Lungpacer Announces IDE for STARI Clinical Study
Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical Trial
March 10, 2025 07:00 ET | Lungpacer Medical USA Inc.
Lungpacer Medical is excited to announce approval of an Investigational Device Exemption (IDE) from the U.S. FDA for the STARI clinical study.
Logo - Lungpacer - Blue.png
Lungpacer Medical Announces Positive Results from STIMULUS Trial: Diaphragm Neurostimulation Improves Hemodynamic Performance During Mechanical Ventilation
February 20, 2025 07:00 ET | Lungpacer Medical USA Inc.
Lungpacer Medical Announces Positive Results from STIMULUS Trial: Diaphragm Neurostimulation Improves Hemodynamic Performance During Mechanical Ventilation
Lungpacer Logo - Blue on Transparent.png
Lungpacer Medical Announces Premarket Approval for AeroPace® System
December 05, 2024 09:00 ET | Lungpacer Medical USA Inc.
EXTON, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Lungpacer Medical, a neurostimulation company dedicated to developing innovative interventional therapies to free patients from mechanical ventilation...
Lungpacer AeroPace PMA Submission Press Release
Lungpacer Medical Announces PMA Submission for AeroPace® System
September 04, 2024 09:00 ET | Lungpacer Medical USA Inc.
Lungpacer Medical today announced that its AeroPace System is under Food and Drug Administration (FDA) review in a premarket approval (PMA) application.
Lungpacer
Lungpacer Medical Accelerates Pivotal Clinical Study with AeroPaceā„¢ System
February 14, 2022 11:49 ET | Lungpacer Medical USA Inc.
EXTON, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPaceā„¢ System, a next generation product,...